Study title:
Clinical Performance of PET/CT in Evaluation of Cancer: Additional Value for Diagnostic Imaging and Patient ManagementRachel Bar-Shalom, MD1; Nikolai Yefremov, MD1; Ludmila Guralnik, MD2; Diana Gaitini, MD2,3; Alex Frenkel, DSc1; Abraham Kuten, MD3,4; Hernan Altman, MBA5; Zohar Keidar, MD, PhD1; and Ora Israel, MD1,3. THE JOURNAL OF NUCLEAR MEDICINE • Vol. 44 • No. 8 • August 2003
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Diagnosis
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: Steripet |
ATC code: |
Document link:
bar-shalom-2003.pdf
|
Document date: 2014-11-18
|
Study number: |
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|